Research programme: eye disorder therapies - Bicycle Therapeutics/ThromboGenics

Drug Profile

Research programme: eye disorder therapies - Bicycle Therapeutics/ThromboGenics

Alternative Names: TG-758; THR 149

Latest Information Update: 16 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bicycle Therapeutics
  • Developer Bicycle Therapeutics; ThromboGenics
  • Class Peptides
  • Mechanism of Action Capillary permeability modulators; Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Eye disorders

Most Recent Events

  • 16 Mar 2017 ThromboGenics plans a phase I/II trial for Diabetic macular oedema in first half of 2018
  • 16 Oct 2014 Preclinical development is ongoing in United Kingdom & Belgium
  • 05 Sep 2013 Preclinical trials in Diabetic macular oedema in Belgium (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top